Search research articles
Contact Us
Filters
Showing results (401-410 of 493) with videos related to
Page
of 50
Sort By:
BJU International
|
April 2, 2020
Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma
Sumanta K Pal, David F McDermott, Michael B Atkins, et al.
Cancer
|
April 6, 2019
A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma
Martin H Voss, Rupal S Bhatt, Nicholas J Vogelzang, et al.
European Urology
|
July 27, 2023
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study
Elizabeth R Plimack, Thomas Powles, Viktor Stus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 18, 2003
Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial
Joseph I Clark, Michael B Atkins, Walter J Urba, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2021
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
David F McDermott, Jae-Lyun Lee, Marek Ziobro, et al.
Journal for Immunotherapy of Cancer
|
July 26, 2024
Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214
Charlene M Mantia, Opeyemi A Jegede, Elizabeth R Plimack, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2022
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Journal of the National Cancer Institute
|
May 3, 2020
Summary From the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research
Toni K Choueiri, Michael B Atkins, Ziad Bakouny, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 16, 2001
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system
C M Balch, S J Soong, J E Gershenwald, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 16, 2001
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma
C M Balch, A C Buzaid, S J Soong, et al.
Page
of 50
Search research articles
Search
Showing results (401-410 of 493) with videos related to
Sort By:
Page
of 50
BJU International
|
April 2, 2020
Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma
Sumanta K Pal, David F McDermott, Michael B Atkins, et al.
Cancer
|
April 6, 2019
A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma
Martin H Voss, Rupal S Bhatt, Nicholas J Vogelzang, et al.
European Urology
|
July 27, 2023
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study
Elizabeth R Plimack, Thomas Powles, Viktor Stus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 18, 2003
Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial
Joseph I Clark, Michael B Atkins, Walter J Urba, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2021
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
David F McDermott, Jae-Lyun Lee, Marek Ziobro, et al.
Journal for Immunotherapy of Cancer
|
July 26, 2024
Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214
Charlene M Mantia, Opeyemi A Jegede, Elizabeth R Plimack, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2022
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Journal of the National Cancer Institute
|
May 3, 2020
Summary From the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research
Toni K Choueiri, Michael B Atkins, Ziad Bakouny, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 16, 2001
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system
C M Balch, S J Soong, J E Gershenwald, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 16, 2001
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma
C M Balch, A C Buzaid, S J Soong, et al.
Page
of 50